{"filings":[{"id":1525838,"accession_number":"0001125345-26-000047","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-07-08T20:00:55+00:00","items":["5.02"],"status":"ready","headline":"MacroGenics board member Karen Ferrante resigns effective Sept 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Karen Ferrante notified the Board of her resignation effective September 1, 2026.","Resignation is for personal reasons and not due to any disagreement with the Company.","The Company thanked Dr. Ferrante for her contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1499722,"accession_number":"0001125345-26-000045","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-07-07T20:30:13+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"MacroGenics completes $122.5M sale of GMP manufacturing to Bora Pharmaceuticals","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of GMP manufacturing (CDMO) to Bora Pharmaceuticals for $122.5M cash, subject to post-closing adjustments.","Bora assumes Rockville, MD facility and Frederick, MD warehouse; ~140 former MacroGenics employees hired by Bora.","MacroGenics enters supply agreement with Bora for process development and drug substance production for pipeline.","Pro forma cash and equivalents rise to $177.2M from $66.5M; estimated gain on sale of $106.1M recorded.","Up to $5M in contingent consideration possible upon manufacturing milestones in 2027-2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554120,"accession_number":"0001125345-26-000042","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-05-20T20:01:01+00:00","items":["5.07"],"status":"ready","headline":"MacroGenics shareholders approve all proposals at 2026 annual meeting, including 1.25M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class I director nominees elected: Scott Koenig, Federica O'Brien, Eric Risser (over 26M votes for each).","Ratified Ernst & Young as independent auditor for FY2026 with 36.7M votes for, 40,552 against.","Advisory say-on-pay approved with 26.6M for, 526k against, 195k abstain.","Amendment to 2023 Equity Incentive Plan approved, increasing authorized shares by 1,250,000.","Voter turnout ~58%; broker non-votes of 9.4M shares on director and advisory proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68722,"accession_number":"0001125345-26-000040","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-05-13T20:22:33+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics reports Q1 loss, divests manufacturing, extends cash runway through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Manufacturing operations sold to Bora Pharmaceuticals for $122.5M upfront; expected to close Q3 2026.","Expanded ZYNYZ royalty monetization with Sagard: $60M received, up to $20M additional milestone.","Q1 2026 net loss $36.8M ($0.58/share) vs $41.0M loss a year ago; revenue $20.8M (up from $13.2M).","Cash and securities $154.2M at March 31, 2026; with proceeds, cash runway extended through 2028.","Pipeline: Initial MGC026 ADC data expected mid-2026; MGC028 data H2 2026; MGC030 IND planned Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22729,"accession_number":"0001125345-26-000035","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-05-12T12:00:15+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MacroGenics sells GMP manufacturing operations to Bora Pharma for $122.5M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Bora pays $122.5M cash at closing for MacroGenics' CDMO business, including Rockville site (11,000 L capacity) and Frederick warehouse.","Up to $5M in additional milestone payments to MacroGenics based on 2027-2028 CDMO manufacturing and professional development services.","Approximately 140 MacroGenics employees expected to be hired by Bora; transaction expected to close in Q3 2026.","MacroGenics will enter supply and transition services agreements to retain clinical manufacturing support for its pipeline.","Transaction approved by both boards; subject to customary closing conditions and consents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91433,"accession_number":"0001125345-26-000032","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MacroGenics receives additional $60M from Sagard in amended ZYNYZ royalty deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $60M cash from Sagard, bringing aggregate royalty purchase price to $130M.","Eligible for up to $20M one-time milestone if ZYNYZ meets specified 2026 net sales thresholds.","Royalty cap: Sagard gets 1.7x investment by Sep 30, 2032 or 2.0x thereafter; then rights revert.","MacroGenics retains all other milestones and economic interests beyond the capped royalty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91432,"accession_number":"0001125345-26-000026","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA removes partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted partial clinical hold on Phase 2 LINNET study of lorigerlimab (bispecific DART targeting PD-1 and CTLA-4).","Revised protocol includes additional risk-mitigation measures for potential hematologic and cardiac toxicities.","MacroGenics plans to resume enrollment in gynecologic cancers (PROC and CCGC); 41 patients dosed to date.","Existing participants continued receiving study drug during the hold; over 300 dosed across all lorigerlimab studies.","Company remains on track to provide a mid-2026 clinical update on the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101511,"accession_number":"0001125345-26-000018","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics reports FY2025 net loss of $74.6M, cash $189.9M; pipeline data catalysts for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $74.6M in 2025 vs $66.9M in 2024; revenue flat at $149.5M; cash $189.9M down from $201.7M.","Phase 1 data for MGC026 (B7-H3 ADC) expected mid-2026; MGC028 (ADAM9 ADC) data in H2 2026.","LINNET study of lorigerlimab under partial clinical hold; update expected mid-2026. IND for MGC030 on track for Q3 2026.","Cash runway guidance extended into late 2027 based on current cash and partner payments.","R&D expenses down 17% to $147.2M; SG&A down 45% to $39.2M due to cost reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101510,"accession_number":"0001125345-26-000011","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Director Jay Siegel to not stand for re-election at MacroGenics' 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Siegel informed the board on February 25, 2026, that he will not stand for re-election as Class I director.","Decision is for personal reasons and not due to any disagreement with the company or its operations.","MacroGenics thanked Dr. Siegel for his contributions to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101509,"accession_number":"0001125345-26-000009","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab after severe safety events","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Partial hold halts new enrollment; current participants may continue receiving lorigerlimab.","Safety events across 4 patients: Grade 4 thrombocytopenia (2), myocarditis (1), neutropenia with septic shock (1) leading to 1 death (Grade 5).","41 patients dosed at 6 mg/kg every 3 weeks in platinum-resistant ovarian and clear cell gynecologic cancer cohorts.","MacroGenics commits to working with FDA to resolve the hold and resume enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117855,"accession_number":"0001125345-25-000111","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CMO Stephen Eck Departs MacroGenics; Frank Perabo Named Interim Lead","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Eck, SVP Clinical Development and CMO, to depart MacroGenics effective Dec 31, 2025 by mutual agreement.","Frank Perabo, VP Clinical Development, will assume interim oversight of clinical development.","Company has retained executive recruiter to search for a new Chief Medical Officer.","Dr. Eck joined MacroGenics in July 2020; will receive standard severance per employment agreement upon signing release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117854,"accession_number":"0001125345-25-000109","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q3 net income $16.8M on $72.8M revenue; ends lorigerlimab prostate study; secures $75M partnership payments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $16.8M ($0.27 diluted EPS) vs $56.3M ($0.90) in Q3 2024; revenue $72.8M down from $110.7M.","Discontinued lorigerlimab in prostate cancer (LORIKEET) after interim data; continues LINNET ovarian study, update by mid-2026.","Received $75M in new partnership payments: $50M from Sanofi (TZIELD milestones), $25M from Gilead (new preclinical program).","Cash $146.4M at Sep 30, expected to add $75M in Q4; runway extended into late 2027.","Three ADC programs advancing: MGC026 started Phase 1 expansion, MGC028 in Phase 1 dose escalation, MGC030 IND planned 2026."],"consensus_eps_estimate":-0.5015,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":108273000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134316,"accession_number":"0001125345-25-000100","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q2 2025 net loss $36.3M; new CEO Eric Risser outlines strategic priorities","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketables $176.5M as of June 30, 2025; cash runway through first half 2027.","Total revenue $22.2M ($15.4M contract manufacturing, $6.9M collaboration vs. $10.8M year ago).","Net loss improved to $36.3M ($0.57/share) from $55.7M ($0.89/share) in Q2 2024.","Eric Risser named President and CEO, succeeding Scott Koenig who stepped down after 24 years.","Received $70M upfront from Sagard Healthcare for ZYNYZ royalty purchase agreement."],"consensus_eps_estimate":-0.6202,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":35434000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134315,"accession_number":"0001125345-25-000094","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MacroGenics appoints Eric Risser as President and CEO, succeeding Scott Koenig","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Risser, previously COO since 2022, becomes CEO and Class I director effective Aug 13, 2025.","Risser receives $625,000 base salary, up to 60% annual bonus, and option for 550,000 shares.","Founding CEO Scott Koenig steps down after 24 years; remains as director and advisor.","Risser led over $1.6B in non-dilutive capital; background includes Johnson & Johnson corporate development.","Severance terms include cash and COBRA; change-in-control triggers faster vesting and 1.5x multiplier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151118,"accession_number":"0001125345-25-000087","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MacroGenics sells ZYNYZ royalty rights to Sagard for $70M; cash runway extended into H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $70M upfront from Sagard for capped royalty on global net sales of ZYNYZ (retifanlimab-dlwr).","After Sagard collects $140M in royalties (2.0x), MacroGenics resumes all future royalty payments.","MacroGenics retains other ZYNYZ economic interests, including development and commercial milestones.","Cash, equivalents and securities were $154.1M at March 31, 2025; combined with $70M, runway now through first half 2027.","ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte in 2017."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151117,"accession_number":"0001125345-25-000075","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MacroGenics annual meeting: all proposals pass, 1.25M share equity plan increase approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four Class III director nominees elected with >43M votes each (Ferrante, Heiden, Hurwitz, Karson).","Ratification of Ernst & Young as auditor approved: 51.3M for, 590K against.","Advisory say-on-pay approved: 42.4M for, 1.38M against.","2023 Equity Incentive Plan amendment (1.25M additional shares) approved: 26.3M for, 17.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151116,"accession_number":"0001125345-25-000054","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q1 2025 net loss improves to $41M; cash runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.0M ($0.65 loss per share) vs Q1 2024 loss of $52.2M ($0.84).","Revenue $13.2M, up from $9.1M, driven by collaborative agreements and contract manufacturing; no product sales after MARGENZA sale.","Cash, equivalents and marketable securities $154.1M as of Mar 31, 2025, down from $201.7M at Dec 31, 2024; runway projected into H2 2026.","First patient dosed in Phase 2 LINNET study of lorigerlimab in platinum-resistant ovarian and clear cell gynecologic cancers.","LORIKEET Phase 2 (lorigerlimab + docetaxel in mCRPC) clinical update expected in second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":13192000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170015,"accession_number":"0001125345-25-000043","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics reports FY2024 net loss of $67M; discontinues vobra duo development","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $67.0M ($1.07 diluted EPS) for FY2024 vs. net loss of $9.1M ($0.15) in FY2023.","Total revenue $150.0M, up from $58.7M in FY2023, driven by $85M milestone from Incyte.","Cash, cash equivalents and marketable securities $201.7M at Dec 31, 2024; cash runway extended into H2 2026.","Discontinuing further internal development of vobra duo; seeking partner; Phase 2 TAMARACK rPFS 9.5-10.0 months.","LORIKEET Phase 2 fully enrolled (150 patients); LINNET Phase 2 in ovarian cancer expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170014,"accession_number":"0001193125-25-036898","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MacroGenics amends CEO Scott Koenig's separation agreement; departure date extended indefinitely","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendment extends CEO Scott Koenig's separation date beyond original Feb 28, 2025; Board will set new date with 14 days notice.","Executive search committee continues identifying next CEO; Board expects conclusion in coming weeks.","Advisory services term extended to 5 years after separation; Koenig receives prorated 2025 annual bonus after departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187034,"accession_number":"0001125345-24-000165","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MacroGenics' VP, Controller & PAO Lynn Cilinski to retire; Beth Smith appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lynn Cilinski to retire as VP, Controller, Treasurer and Principal Accounting Officer effective Jan 2, 2025, after 21 years at company.","Beth Smith, current Executive Director of Accounting and Assistant Controller since 2022, appointed as successor effective same date.","Smith holds a B.S. in Accounting from Bucknell University; no family relationships or transactions requiring disclosure.","Company will file amendment if material plan, contract, or arrangement is entered into with Smith."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187033,"accession_number":"0001125345-24-000161","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q3 net income $56.3M; cash runway into 2026; MARGENZA sale progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $56.3M ($0.90 diluted EPS) vs $17.6M in Q3 2023; revenue $110.7M driven by $100M Incyte milestone.","Cash $200.4M at Sep 30; plus $40M MARGENZA upfront from TerSera, less $8M fee; runway into 2026.","MARGENZA sale to TerSera for $40M upfront + up to $35M milestones; closing expected Q4 2024.","IND for ADAM9-targeting ADC MGC028 submitted; TAMARACK mCRPC study continues, rPFS data early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":130609000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187032,"accession_number":"0001193125-24-247017","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"MacroGenics CEO Scott Koenig to step down; search committee formed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Koenig to depart as President and CEO effective Feb 28, 2025; will resign from Board on same date.","Separation includes 24 months salary continuation, target bonus, COBRA, and accelerated vesting of 50% of unvested equity.","Continuing as advisor until Feb 28, 2030, with continued vesting of remaining unvested equity awards.","Board formed special committee and retained Heidrick & Struggles to identify new CEO.","Company highlights strong balance sheet and pipeline of antibody-based cancer therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203571,"accession_number":"0001125345-24-000151","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics TAMARACK Phase 2 data: 6-month rPFS 69-70%, ORR up to 40.6%, but 8 treatment-related deaths","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6-month radiographic PFS rate 69% (2.0 mg/kg) and 70% (2.7 mg/kg); median rPFS ~8.5 and 7.5 months (immature).","Confirmed ORR 20.0% (2.0 mg/kg) and 40.6% (2.7 mg/kg) among RECIST-evaluable patients.","Median 6 doses received (range 1-12); 25.6% (2.0 mg/kg) and 18.6% (2.7 mg/kg) remained on drug at data cutoff.","Grade ≥3 TEAEs: 65.6% (2.0 mg/kg) and 62.8% (2.7 mg/kg); discontinuation rates 25.6% and 38.4%.","8 fatal treatment-related AEs (5 in 2.0 mg/kg, 3 in 2.7 mg/kg) including pneumonitis and cardiac events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203570,"accession_number":"0001125345-24-000149","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q2 net loss $55.7M; receives $100M Incyte milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.7M ($0.89 diluted EPS) vs net income of $57.5M in Q2 2023.","Revenue of $10.8M, down from $13.1M YoY, driven by lower Provention revenue.","Cash $140.4M at June 30; $100M Incyte milestone received post-quarter extends cash runway into 2026.","TAMARACK Phase 2 mCRPC data (vobra duo) to be presented at ESMO in September 2024.","MGC028 IND expected by end 2024; LORIKEET Phase 2 enrollment completion anticipated in 2024/early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":19901000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203569,"accession_number":"0001125345-24-000141","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics discontinues vobra duo dosing in TAMARACK Phase 2 mCRPC study on IDMC safety recommendation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommended stopping dosing for remaining participants; most had received 8-12 cycles.","Emerging adverse events from prolonged exposure cited; participants continue safety and survival follow-up.","Primary endpoint 6-month rPFS data to be presented at ESMO Congress September 2024.","Company will not hold Q2 2024 earnings call; financial results release expected August 6.","Investor conference call planned after ESMO presentation to discuss next steps for vobra duo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203568,"accession_number":"0001125345-24-000140","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics receives $100M milestone payment from Incyte for retifanlimab collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MacroGenics and Incyte amended their 2017 collaboration agreement, deeming milestones achieved and triggering a $100M payment to MacroGenics.","MacroGenics confirms cash runway guidance into 2026, supported by the $100M milestone plus expected partner payments and product revenues.","Total milestones achieved from Incyte now reach $215M since the initial 2017 collaboration.","Retifanlimab (ZYNYZ) is a PD-1 inhibitor for Merkel cell carcinoma, originally developed by MacroGenics and licensed to Incyte.","MacroGenics remains eligible for up to $210M in development/regulatory milestones and $330M in commercial milestones from Incyte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220049,"accession_number":"0001125345-24-000124","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MacroGenics stockholders approve all four proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class II directors: Scott Jackson, Margaret A. Liu, David Stump, with majority 'for' votes.","Ratified Ernst & Young as independent auditor for FY 2024 (53.5M for, 2.1M against).","Advisory say-on-pay approved with 49.5M 'for' votes.","Approved amendment to 2023 Equity Incentive Plan increasing authorized shares by 2M.","Meeting turnout: ~89% of outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220048,"accession_number":"0001125345-24-000091","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q1 net loss $52.2M; interim TAMARACK data shows vobra duo activity in mCRPC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $52.2M ($0.84/share) vs $38.0M loss in Q1 2023; total revenue $9.1M, down from $24.5M.","Cash, equivalents and marketable securities $184.2M as of March 31, 2024; cash runway expected into 2026.","Interim TAMARACK data: vobra duo 2.0 mg/kg q4W showed confirmed PSA≥50% reduction in 36/82 (43.9%) and ORR of 17.8%.","Five fatal AEs reported in TAMARACK; two pneumonitis deaths in 2.7 mg/kg cohort; Phase 3 planning initiated for 2025.","Company plans to expand TAMARACK to NSCLC, SCLC, melanoma and other indications in mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":9104000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220047,"accession_number":"0001125345-24-000090","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics posts corporate presentation with Phase 2 interim data (TAMARACK trial)","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation posted May 9, 2024; data cut-off April 12, 2024.","Presentation includes Phase 2 interim data from TAMARACK trial.","No specific numerical results disclosed in the 8-K excerpt; full presentation on company website.","Investors should review the complete presentation for material clinical updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220046,"accession_number":"0001125345-24-000065","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics Phase 2 TAMARACK safety data shows improved tolerability at lower vobra duo doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Drug interruption rate 12.6% vs 58.5% at 12 weeks in Phase 1; discontinuation 5.3% vs 14.6%.","No fatal AEs; most common TEAEs: asthenia (40.7%), nausea (27.7%), fatigue (20.3%).","ASCO abstract not accepted; plan to share updated interim safety + efficacy by May 31, 2024.","rPFS primary endpoint data expected Fall 2024; IDMC recommended study continue unchanged.","Enrolled 182 mCRPC patients across 2.0 and 2.7 mg/kg Q4W dose arms; 85.7% still on treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239784,"accession_number":"0001125345-24-000061","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics reports FY2023 net loss of $9.1M; cash $229.8M; vobra duo data at ASCO 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.1M vs $119.8M in 2022; revenue $58.7M (down 61% YoY) due to lower collaboration revenue.","Cash, equivalents & securities $229.8M as of Dec 31, 2023, up from $154.3M; cash runway into 2026.","Preliminary TAMARACK Phase 2 data for vobra duo in mCRPC expected at ASCO 2024; 177 patients enrolled.","Initiated Phase 1 dose escalation of MGC026 (topoisomerase I inhibitor-based ADC) in advanced solid tumors.","Received $100M from sale of TZIELD royalty interest and $50M milestone from Sanofi, recorded as $150.9M gain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257295,"accession_number":"0001125345-23-000125","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q3 net income $17.6M ($0.28 EPS); cash $256.4M; TAMARACK enrollment ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $17.6M ($0.28 diluted EPS) vs net loss $24.8M in Q3 2022; revenue $10.4M down from $41.7M.","Cash and marketable securities $256.4M; expect cash runway into 2026; received $15.7M Gilead milestone and $50M Sanofi milestone in Q3.","Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule; data readout expected H1 2024.","Initiated LORIKEET Phase 2 of lorigerlimab in mCRPC; IND submitted for MGC026 ADC; Phase 1 to start Q1 2024.","R&D expenses $30.1M (down from $48.2M); SG&A $12.4M (down from $15.4M); shares outstanding 62.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":48029000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274626,"accession_number":"0001125345-23-000113","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"MacroGenics amends TZIELD royalty deal; retains $50M sales milestone and 50% royalty share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Royalty Purchase Agreement with DRI; Aventis (Sanofi sub) now receives royalty directly from Provention Bio.","Asset Purchase Agreement amended to include $50M milestone payment from Sanofi if TZIELD net sales hit certain level.","MacroGenics retains 50% royalty on global TZIELD sales above an annual threshold.","Sanofi guarantees the $50M sales milestone obligation to MacroGenics.","All prior obligations under the Royalty Purchase Agreement eliminated as of September 19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274625,"accession_number":"0001125345-23-000109","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q2 net income $57.5M on royalty gain; $50M TZIELD milestone from Sanofi","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $57.5M ($0.92 diluted EPS) vs net loss of $41.3M a year ago; driven by $100.9M gain on royalty monetization.","Total revenue $13.1M, down from $26.0M YoY; collaborative revenue fell to $6.0M from $16.9M.","Cash $240.3M; plus $50M Sanofi milestone; cash runway extends into 2026.","Pipeline: TAMARACK Phase 2 for vobra duo in mCRPC enrolling under amended protocol; lorigerlimab Phase 2 to start.","Received $50M milestone from Sanofi after positive TZIELD Phase 3 data; additional $50M possible if net sales threshold met."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":37632000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291932,"accession_number":"0001125345-23-000081","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MacroGenics stockholders elect directors, approve 2023 equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class I directors elected: Koenig, O'Brien, Siegel; each with over 41M votes for.","Ernst & Young ratified as independent auditor for FY 2023 with 47.6M for vs 5.0M against.","Advisory vote on named executive officer compensation approved with 43.6M for (non-binding).","2023 Equity Incentive Plan approved with 32.3M for, 16.8M against; broker non-votes 3.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291931,"accession_number":"0001125345-23-000077","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics reports Q1 net loss $38M; cash runway through 2025 on $270M non-dilutive funding","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.0M ($0.61 loss per share) vs. $66.4M loss year ago; revenue $24.5M (up 121% YoY).","Cash, equivalents & marketable securities $241.7M at March 31, 2023; additional $30M approval milestone from TZIELD received after Q1.","ZYNYZ (retifanlimab) approved by FDA for MCC; MacroGenics received $15M milestone, eligible for up to $650M more plus tiered royalties.","Sold TZIELD royalty interest to DRI for $100M upfront; retains 50% share above threshold and up to $430M in Sanofi milestones.","Phase 2 TAMARACK (vobra duo in mCRPC) enrollment under revised protocol to start Q2 2023; clinical update expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":24496000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312687,"accession_number":"0001125345-23-000063","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics to receive $15M milestone from Incyte after FDA approval of ZYNYZ","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MacroGenics will receive $15M milestone payment from Incyte after FDA approval of ZYNYZ (retifanlimab-dlwr) for Merkel cell carcinoma.","ZYNYZ, a PD-1 inhibitor, was originally developed by MacroGenics and licensed to Incyte in October 2017.","This marks the third product approval from MacroGenics' pipeline of proprietary or partnered candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312686,"accession_number":"0001125345-23-000058","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics reports 2022 net loss of $119.8M; cash runway extended through 2025 via $250M non-dilutive funding","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $119.8M ($1.95/share) vs $202.1M in 2021; revenue $151.9M (up 96% YoY).","Cash $154.3M at Dec 2022; plus $100M from DRI royalty sale; runway through 2025.","TAMARACK trial modified: removed control arm; clinical update expected in 2024.","Lorigerlimab mCRPC data: 28.6% PSA50, 25.7% confirmed partial responses.","TZIELD approval milestone: two $15M payments received; two due by Sept 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312685,"accession_number":"0001125345-23-000047","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MacroGenics discloses no exposure to Silicon Valley Bank deposits or securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company confirms it holds no cash deposits or securities at Silicon Valley Bank.","Disclosure made on March 10, 2023, amid SVB's collapse and bank run.","No financial impact from SVB failure expected; liquidity position unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312684,"accession_number":"0001125345-23-000045","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MacroGenics sells TZIELD royalty to DRI for up to $200M; $100M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $100M for single-digit royalty on global net sales of TZIELD.","MacroGenics retains a 50% share of royalty above an annual threshold.","Eligible for up to $50M milestone tied to TZIELD advancement in newly diagnosed type 1 diabetes.","Potential additional $50M if TZIELD achieves a specified net sales level.","Closing expected March 15, 2023; MacroGenics keeps other regulatory and commercial milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312683,"accession_number":"0001125345-23-000021","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics reports preliminary Phase 1 lorigerlimab data; 28.6% PSA50 in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12 of 42 mCRPC patients (28.6%) achieved ≥50% PSA reduction; 9 of 42 (21.4%) achieved ≥90% PSA reduction.","9 of 35 evaluable patients (25.7%) had confirmed partial responses; median duration 4.6 months.","TRAEs in 86.6% of patients; grade ≥3 TRAEs in 34.6%; 24.4% discontinued due to AEs; no fatal TRAEs.","Company plans to initiate Phase 2 study in mCRPC in 2023.","Median prior therapies: 2; 83% had prior docetaxel, 81% prior androgen receptor antagonist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312682,"accession_number":"0001125345-23-000011","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MacroGenics appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective January 3, 2023; Liu joins Science & Tech Committee, Karson joins Audit Committee.","Board expands to ten directors, nine of whom are independent.","Dr. Liu is a gene therapy, vaccines, and immunotherapy expert; former exec at Merck and Chiron.","Meenu Chhabra Karson is a biopharma executive; previously CEO of Proteostasis Therapeutics and led its IPO.","Karson received an option to purchase 36,000 shares vesting monthly over 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331193,"accession_number":"0001125345-22-000113","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MacroGenics appoints Margaret Liu, M.D. to Board of Directors effective Jan 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Liu will serve as a Class II director until the 2024 Annual Meeting or until successor is elected.","She has been appointed to the Science & Technology Committee, effective January 3, 2023.","Initial grant of option to purchase 36,000 shares vesting monthly over 36 months from grant date.","Annual retainer and compensation per the Company's Director Compensation Program as disclosed in April 2022 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331192,"accession_number":"0001125345-22-000111","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"MacroGenics extends office lease to 2035, with options to 2045","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended lease for 122,600 sq ft at Rockville, MD headquarters; term now ends Dec 31, 2035.","Base rent starts at $46.37/sq ft, escalating 3% annually; two 5-year extension options to 2045.","Landlord grants 50% rent abatement for first 24 months of the modified term.","Lease originally ran to Aug 2027; amendment executed Dec 14, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331191,"accession_number":"0001125345-22-000108","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics earns $60M milestone from Provention on FDA approval of teplizumab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved teplizumab BLA for type 1 diabetes; MacroGenics receives $60M milestone from Provention.","Total potential regulatory milestones from Provention up to $170M; additional $225M in sales milestones.","Single-digit royalty on net sales of teplizumab payable to MacroGenics.","Cash runway extended into late 2024 based on existing cash and anticipated partner payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331190,"accession_number":"0001125345-22-000103","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q3 net loss narrows to $24.8M; receives $60M Gilead upfront; cash runway into mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $41.7M (up from $15.7M YoY) including $30M Incyte milestone and $4.4M MARGENZA sales.","Net loss $24.8M ($0.40/share) vs $52.9M ($0.86/share) in Q3 2021; R&D spend $48.2M.","Cash $123.6M at Sep 30, plus $60M from Gilead in Oct; cash runway extended into mid-2024.","Gilead collaboration for MGD024 and up to two bispecific programs; potential $1.7B in milestones plus tiered royalties.","Teplizumab PDUFA date Nov 17, 2022; if approved, MacroGenics eligible for $60M milestone from Provention Bio."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":78842000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331189,"accession_number":"0001125345-22-000092","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MacroGenics and Gilead sign $60M upfront option deal for MGD024 and two bispecific programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $60M from Gilead; potential milestones up to $1.7B for MGD024 and two research programs.","Gilead gets exclusive option to license MGD024 (Phase 1 CD123×CD3 DART) for AML and MDS.","MacroGenics to continue Phase 1 study; Gilead may exercise option at predefined decision points.","Tiered double-digit royalties on MGD024 net sales; flat royalties on products from two research programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348759,"accession_number":"0001125345-22-000089","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MacroGenics Q2 net loss $41.3M; cuts 15% workforce, extends cash runway to 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.3M vs $39.9M YoY; cash $133.7M at June 30, plus $34.5M in July payments from partners.","Workforce reduction of ~15% and closure of Brisbane and Rockville sites to reduce costs.","Received $30M milestone from Incyte; $60M milestone due upon teplizumab approval (PDUFA Nov 17, 2022).","Plan to start MGC018 Phase 2/3 TAMARACK study in mCRPC by year-end; interim data from Phase 2 by end 2024.","Lorigerlimab Phase 1/2 enrollment complete; data update expected early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":37108000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348758,"accession_number":"0001125345-22-000080","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MacroGenics closes Phase 2 enoblituzumab study after 7 hemorrhagic fatalities in head and neck cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 study CP-MGA271-06 closed due to 7 fatal hemorrhagic events among 62 SCCHN patients.","6 of 7 deaths assessed as unrelated to study treatment; 1 possibly related; incidence exceeded literature rate of 1–3.6%.","Prior enoblituzumab studies in >340 patients had <1% fatal hemorrhage; nonclinical tox showed no coagulopathy.","Company informed FDA and investigators; no new patients enrolled or treated as of July 7, 2022.","Closure does not affect ongoing MGC018 ADC program; internal review and data analysis continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365531,"accession_number":"0001125345-22-000070","cik":1125345,"company_name":"MACROGENICS INC","ticker":"MGNX","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MacroGenics appoints William Heiden as Board Chair, replacing Paulo Costa","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Heiden appointed as non-executive Chair of the Board and director, effective May 22, 2022.","Heiden replaces Paulo Costa, whose term expired at 2022 Annual Meeting on May 19.","Heiden also appointed to Audit Committee; granted option to purchase 36,000 shares at $3.96, vesting monthly over 36 months.","Board now comprises 8 directors, 7 of whom are independent.","Heiden brings 35 years biopharma experience, most recently CEO of AMAG Pharmaceuticals (acquired 2020 for $650M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274668969.3372603,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-24T23:59:59+00:00|365531"}